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Poster Session I S2650.73). All patients underwent HSCT for malignancies and none who
received a reduced intensity HSCT have developed a SMN to date.
Of those with exostoses, 1 patient had received autologous HSCT
and underwent allogeneic HSCT for myelodysplastic syndrome.
The other SMNs in this group include thyroid papillary carcinoma,
osteogenic sarcoma, GIST, PNET. 3 of 4 SMNs in the control
group had received allogeneic HSCT and all 4 had thyroid papillary
carcinoma. Matched data analysis showed that exostosis cases were
less likely to have been treated with steroids for acute GVHD
(McNemar test p5 0.022) but no differences existed in other clinical
variables examined. However, cases were younger at HSCT (3.9 vs
6.3 yrs, paired t-test p 5 0.004) and had longer F/U than controls
(11.7 vs 8.8 yrs, p 5 0.003). There was no difference in time from
HSCT to SMN (or latest F/U) by Kaplan-Meier (cases5 14.9, con-
trol 5 12.7 yrs, log rank p 5 0.35). Among all 52 patients without
considering exostosis, the age at HSCT was not different for those
with SMN than without (p5 0.87). Descriptive analyses comparing
SMN occurrence in exostosis cases and controls appears in the at-
tached table. In conclusion, for occurrence of exostoses our study
showed only acute GVHD to be different between the groups, and
the likelihood of SMN was similar for cases and controls. Of the
10 SMNs, 50% were thyroid carcinomas, which are common after
low dose radiation exposure to the thyroid.Of note, 43%of the other
solid SMNs among this group occurred in the field of focal radiation
for the primary tumor, highlighting the importance of high dose fo-
cal radiation as a SMN risk.305
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Myeloablative AlloSCT is associated with 20-40% non-relapse
mortality (NRM) in the first 100 days. NRM depends in large part
on graft source, disease and disease status and possibly intensity of
conditioning. RTC may decrease NRM but pediatric data are lim-
ited (Satwani/Cairo BBMT, 2005). We evaluated the feasibility
and toxicity of RTC-AlloSCT in 100 consecutive children (median
age 9.2366.79 yrs) with malignant disease (50) or non-malignant
disease (50) undergoing UCB (n 5 51), MFD (n 5 41), or MUD
(n 5 8) AlloSCT (89 average risk, 11 high risk). Regimens included
Busulfan (6.4-8mg/kg) + Fludarabine (150-180mg/m2) 6 ATG
(8mg/m2) (n 5 45); Cyclophosphamide (60mg/kg) + Fludarabine
(150mg/m2) 6 ATG (8mg/m2) (n 5 20); and Busulfan (12.8-
16mg/kg) + Fludarabine (150mg/m2) + Alemtuzumab (54mg/m2)
(n 5 35). Mean follow-up is 1277 61041 days. Time to neutrophil
and platelet engraftment was 19 610 days and 35 6 26.6 days, re-
spectively. Donor chimerism on day 30, 100 and 365 was 86 627,
92.6 615.8 and 93616, respectively. Cumulative incidence of
aGVHD and cGVHDwas 24.7%64.8% and 18.6%64.7%, respec-
tively. Day 100 and 5 year NRM was 4.1%62.01% and 1563.9 %,
respectively. Overall incidence of primary graft failure (PGF) was
16.5%63.7%. Incidence of PGF with UCB was 33.3%66.8% vs.
0% for MUD and MSD (p \ 0.0001). Incidence of PGF with
UCB in chemo-naive vs. non-chemo-naive patients was 48.3%6
9.3% vs. 10.5%67 % (p\ 0.0072). The 5 year probability of OS
and EFS was 69%65% and 56.4%65.4%, respectively. On univar-
iate analysis, age (p 5 0.12), malignant disease (p 5 0.1), UCB (p 5
0.02), poor risk disease (p 5 0.001), chemo-naive patients (p 5 0.1),
fungal infection (p5 0.01), alemtuzumab based RTC (p5 0.03) and
PGF (p 5 0.03) were associated with poor OS. However, on Cox
proportional hazardmodel basedmultivariate analysis only graft fail-
ure (p5 0.028) and poor risk disease (p5 0.03) were associated withpoor OS. In summary, in this largest reported pediatric series, RTC-
AlloSCTdemonstrated substantially reduced day 100NRMand sus-
tained donor chimerism. However, chemo-naive children undergo-
ing RTC-AlloSCT with UCB grafts have a higher incidence of
PGF, and poor OS.306
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Background: Steroid-refractory acute gastrointestinal graft-versus-
host disease (GvHD) remains major cause of mortality in pediatric
patients undergoing hematopoietic stem cell transplantation
(HSCT). Among newly developed agents suitable for the treatment
of GvHD, monoclonal antibodies hold much promise.
Methods: we report a series of 10 children who underwent alloge-
neic transplant from June 2007 through June 2009 and were treated
with daclizumab for steroid-refractory acute GI GvHD (grade III-
IV). Median of patients’ age was 6.27 years (range 1-11) and 8 of pa-
tients were male. 8 of 10 patients underwent myeloablative and 2 of
them nonmyeloablative stem cell transplant. Bonemarrow (BM), pe-
ripheral blood (PB), and cord blood were stem cell sources in 4 pa-
tients, 3 patients and one patient respectively. Additionally, double
cord blood in one patient and BM and PB concurrently in another
one were used. Patients were transplanted from full match related
(n5 6), one locus mismatch related (n5 1), two locus mismatch un-
related (n 5 2) and haploidentical related (n 5 1) donor because of
Thalassemia (n5 4), Acute Lymphoblastic Leukemia (n5 2), Aplas-
tic Anemia (n 5 1), Fanconi Anemia (n 5 1), Leukocyte Adhesion
Deficiency (n 5 1), and Wiskott-Aldrich Syndrome (n 5 1). After
first line therapy failed to control GvHD, Daclizumab added at
a dose of 1 mg/kg every 10-14 days until response achieved and/or
maximum 5 doses administered.
Results: 9 of 10 patients (90%) responded to Daclizumab therapy
completely, but one patient failed. There were no infusion-related
reactions. 8 patients developed CMV infection during Daclizumab
therapy. Invasive fungal and bacterial infections occurred in 6 pa-
tients following Daclizumab therapy. Seizure and Guillain-Barre
were important complications after daclizumab therapy in two pa-
tients which may be attributable to this monoclonal antibody. At
a median follow-up of 460 days, 8 patients (80%) are alive and free
of GvHD, severe infections and underlying disease. The remaining
two patients died because of bacterial meningitis and severe non-re-
sponding acute GI GvHD. Limited Chronic GvHD, occurred in 2
patients.
Conclusions:Daclizumab was able to induce complete responses in
pediatric patients with refractory acute gastrointestinal GvHD, but
is associated with morbidity and mortality due to infectious compli-
cations. Aggressive prophylaxis against viral and fungal infections is
recommended.307
A PROSPECTIVE STUDY OF REDUCED INTENSITY CONDITIONING (RIC)
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Reduced intensity conditioning (RIC) reduces transplant related
morbidity and mortality. However, engraftment remains a challenge
after RIC in children with non-malignant disorders undergoing
UCBT.We designed a novel RIC regimen for such children to study
its efficacy to promote durable engraftment. Outcomes of 8 such
children enrolled between Dec 2008 and July 2010 are presented
in this preliminary analysis. RIC regimen consisted of alemtuzumab
(3.2mg/kg), hydroxyurea (HU), fludarabine (FLU) 150 mg/m2,
